Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.

Aug 18, 2023 - 20:00

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.

Read the original article

Tags:

Previous Article

Boehringer Ingelheim advances weight loss drug to Phase III trials

Signal: Abortion pill restriction may drive more patients to off-label drug

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: UnitedHealth says medical costs aren’t soaring. The reality is murkier

STAT+: UnitedHealth says medical costs aren’t soaring. ...

Apr 15, 2023

Gilead reports 8.45% dip in net income for Q2 2023

Gilead reports 8.45% dip in net income for Q2 2023

Aug 4, 2023

Superbugs, antibiotic resistance get renewed scrutiny in Congress

Superbugs, antibiotic resistance get renewed scrutiny i...

Jul 12, 2023